Media

New Concepts in ADT- Thomas Keane

Details
(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...

Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas

Details
(Length of Discussion: 30 min) Petros Grivas and Alicia Morgans discuss the progress in systemic and immunotherapy in advanced bladder cancer. They discuss the biologic and immunologic background of urothelial cancer that paves the way for the development of potential biomarkers, as well as possible therapeutic targets in this disease. They share insights on the significant advances in systemic th...

Sleep Hygiene and Nocturia - Jeffrey Weiss

Details
Jeffrey Weiss discusses the importance of sleep hygiene with Diane Newman and the relationship between disordered sleep and nocturia. They highlight the standard number of hours of sleep a night for quality of life as well as the relationship of sleep cycles and nocturia. Jeffrey fields Diane's questions on dietary irritants that can lead to impaired sleeping, the importance of voiding diaries and...

nmCRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans

Details
(Length of Conversation: 24 min) Alicia Morgans and Charles Ryan discuss data that was presented at the ASCO GU 2018 meeting including two phase III trials, Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer ( SPARTAN ) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer ( PROSPER ) and the advances fo...

Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans

Details
Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Read Mor...

Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety

Details
Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. Biographies: Badrinath Konety, MD, MBA , is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-Oncology and is Director of the...

Joining Forces to Address Unanswered Questions - The European PEACE Consortium - Interview with Karim Fizazi

Details
Karim Fizazi and Alicia Morgans discuss various treatment data in the metastatic hormone-sensitive space, including the LATITUDE, CHAARTED and STAMPEDE trials. The European Consortium Prostate Cancer Consortium in Europe (PEACE) trials were designed for the current generation of prostate and advanced prostate cancer patients and was established in 2013 to facilitate large academic clinical trials...

The Utility of PSMA PET In Prostate Cancer Management- Stefano Fanti

Details
(Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...

nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

Details
(Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...

Treating the Nocturia Patient - Diane Newman

Details
Benjamin Brucker and Diane Newman discuss the nocturia patients she identifies and treats in her practice, the bothers they experience from nighttime awakenings, and sleep disruption outcomes in her patients' daily life. They also discuss conservative treatment approaches and antimuscarinic medications for overactive bladder. Biographies: Diane K. Newman, DNP, FAAN, BCB-PMD Benjamin M. Brucker, MD...